

Anti-Complement Factor D Reference Antibody (lampalizumab)

Recombinant Antibody Catalog # APR10146

Specification

Anti-Complement Factor D Reference Antibody (lampalizumab) - Product Information

Application
Primary Accession
Reactivity
Clonality
Isotype

Calculated MW

FC, Kinetics, Animal Model

<u>P00746</u>

Human, Rabbit Monoclonal

lgG1

143.8 KDa

Anti-Complement Factor D Reference Antibody (lampalizumab) - Additional Information

Target/Specificity
Complement Factor D

Endotoxin

< 0.001EU/ µg, determined by LAL method.

Conjugation Unconjugated

Expression system

CHO Cell

Format

Purified monoclonal antibody supplied in PBS, pH6.0, without preservative. This antibody is purified through a protein A column.

Anti-Complement Factor D Reference Antibody (lampalizumab) - Protein Information

Name CFD (HGNC:2771)

Synonyms DF, PFD

Function

Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:21205667, PubMed:22362762, PubMed:6769474, PubMed:874324, PubMed:9748277, PubMed:9748277). In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the spontaneous hydrolysis of complement C3 (PubMed:<a



href="http://www.uniprot.org/citations/21205667" target="_blank">21205667, PubMed:22362762, PubMed:6769474, PubMed:874324). The alternative complement pathway acts as an amplification loop that enhances complement activation by mediating the formation of C3 and C5 convertases (PubMed:21205667, PubMed:22362762, PubMed:6769474, PubMed:874324). Activated CFD cleaves factor B (CFB) when the latter is complexed with complement C3b, activating the C3 convertase of the alternative pathway (PubMed:<a

 $\label{lem:http://www.uniprot.org/citations/21205667" target="_blank">21205667, PubMed:6769474, PubMed:874324, PubMed:9748277).$


Cellular Location Secreted

Anti-Complement Factor D Reference Antibody (lampalizumab) - Protocols

Provided below are standard protocols that you may find useful for product applications.


- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- Immunofluorescence
- Immunoprecipitation
- Flow Cvtometv
- Cell Culture

Anti-Complement Factor D Reference Antibody (lampalizumab) - Images




Anti-Complement Factor D Reference Antibody (lampalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%





The purity of Anti-Complement Factor D Reference Antibody (lampalizumab)is more than 99.38% ,determined by SEC-HPLC.



Immobilized human Complement Factor D, Fc at 2 μ g/mL can bind Anti-Complement Factor D Reference Antibody (lampalizumab) \square EC50=0.02371 μ g/mL